Gynecologic solid tumors: cross-border specialty drug access for international patients

Quick orientation

Cervical, endometrial, ovarian, and other gynecologic cancers collectively are major causes of cancer mortality in women globally. Cervical cancer is particularly relevant in low-resource settings due to limited screening access.

Typical age of onset. Adulthood; subtype-specific.

Severity tiers. Severity depends on subtype, stage, and molecular profile.

Why specialty drugs for Gynecologic solid tumors are hard to access internationally

Several recent FDA approvals for endometrial cancer (immunotherapy), ovarian cancer (PARP inhibitors, antibody-drug conjugates), and cervical cancer (tissue-factor ADCs) have changed practice. International registration is uneven.

Treatments approved by the FDA

• Tivdak (tisotumab vedotin-tftv) — FDA approval: 2021. Mechanism: Tissue factor-directed antibody-drug conjugate for cervical cancer. Route: Intravenous infusion every 3 weeks. US WAC ballpark: Approximately USD 210,000 per year. Country pricing: UAE · Bahrain.
• Jaypirca (pirtobrutinib) — FDA approval: 2023. Mechanism: Non-covalent BTK inhibitor (CLL/MCL labels; some off-label exploration). Route: Oral once daily. US WAC ballpark: Approximately USD 250,000 per year. Country pricing: Saudi Arabia · Kuwait · Egypt · Jordan · Bahrain.
• Orserdu (elacestrant) — FDA approval: 2023. Mechanism: Oral SERD for ESR1-mutated HR+ HER2- breast cancer (adjacent endocrine-driven gynecologic oncology). Route: Oral once daily. US WAC ballpark: Approximately USD 220,000 per year. Country pricing: Saudi Arabia · Egypt.

Cross-border pathways used for Gynecologic solid tumors

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Expanded Access Program (EAP)
• Compassionate Use
• Personal Import Scheme

What your physician needs to know

• Confirm subtype, molecular profile, and stage.
• Document prior systemic therapy.
• Multidisciplinary gynecologic oncology team co-manages.
• Watch for class-specific adverse events.

Common questions

Are these drugs available in my country?

Registration varies. We confirm by destination.

How is molecular testing handled?

Where local testing is unavailable, samples can be referred to qualified labs.

How long does shipment take?

Five to fifteen business days from prescription receipt.

What documents are required?

Gynecologic oncologist's prescription, pathology with molecular profile, imaging, and treatment history.

Can immunotherapy be combined with chemotherapy?

Several approved regimens combine. Your oncologist decides.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Gynecologic solid tumors, our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Gynecologic solid tumors

Reserved for you.